Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

Cancer Science

Volumn 101, Issue 3, 2010, Pages 826-830

  Demicheli, Romano ^a   Biganzoli, Elia ^b   Ardoino, Ilaria ^a   Boracchi, Patrizia ^b   Coradini, Danila ^b   Greco, Marco ^a   Moliterni, Angela ^c   Zambetti, Milvia ^c   Valagussa, Pinuccia ^c   Gukas, Isaac D ^d   Bonadonna, Gianni ^c  

^a IRCCS Foundation   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; RISK ASSESSMENT;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN;

EID: 77949681150     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01472.x     Document Type: Article

References (36)

1. Knight WA, Livingston RB, Gregory EJ. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977, 37:4669-71.
2. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988, 15:20-5.
3. Raemaekers JM, Beex LVAM, Joenders AJM. The breast cancer group: disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat 1985, 6:123-30.
4. Hess KR, Pustzai L, Buzdar AU. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003, 78:105-18.
5. Gray RJ. Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. J Am Stat Assoc 1992, 87:942-51.
6. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-46.
7. Coradini D, Daidone MG, Boracchi P. Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol 2000, 18:2702-9.
8. Hilsenbeck SG, Ravdin PM, de Moor CA. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998, 52:227-37.
9. Clemmesen J. Carcinoma of the breast. Results from statistical research. Br J Radiol 1948, 21:583-90.
10. Anderson WF, Chatterjee N, Ershler WB. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002, 76:27-36.
11. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 2005, 90:127-37.
12. Anderson WF, Chen BE, Jatoi I. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 2006, 100:121-6.
13. Sorlie T, Wang Y, Xiao C. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127.
14. Gruvberger S, Ringner M, Chen Y. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61:5979-84.
15. Demicheli R, Retsky MW, Hrushesky WJM. Tumor dormancy and surgery-driven dormancy interruption in breast cancer: learning from failures. Nat Clin Pract Oncol 2007, 4:699-710.
16. Demicheli R, Retsky MW, Hrushesky WJM. Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer 2007, 110:1880-8.
17. Demicheli R, Valagussa P, Bonadonna G. Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy. Breast Cancer Res Treat 2002, 75:127-34.
18. Veronesi U, Saccozzi R, Del Vecchio M. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981, 305:6-11.
19. Moliterni A, Bonadonna G, Valagussa P. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991, 9:1124-30.
20. Buzzoni R, Bonadonna G, Valagussa P. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991, 9:2134-40.
21. Ramlau-Hansen H. Smoothing counting process intensities by means of Kernel functions. Ann Stat 1983, 11:453-66.
22. Boracchi P, Biganzoli E, Marubini E. Joint modeling of cause specific hazard functions with cubic splines: an application to a large series of breast cancer patients. Comput Stat Data Anal 2003, 42:243-62.
23. Clarke RB. Steroid receptors and proliferation in the human breast. Steroids 2003, 68:789-94.
24. Ding SL, Sheu LF, Yu JC. Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci 2004, 11:911-9.
25. Jensen EV, Cheng G, Palmieri C. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 2001, 98:15197-202.
26. Surowiak P, Paluchowski P, Wysocka T. Steroid receptor status, proliferation and metallotionein expression in primary invasive ductal breast cancers. Pathol Oncol Res 2004, 4:207-11.
27. Demicheli R, Terenziani M, Bonadonna et al.. Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? Breast Cancer Res Treat 1998, 51:133-7.
28. Demicheli R, Bonadonna G, Hrushesky WJM. Menopausal status dependence of the timing of breast cancer recurrence following primary tumor surgical removal. Breast Cancer Res 2004, 6:R689-96.
29. Pearlman NW, Jochimsen PR. Recurrent breast cancer: factors influencing survival, including treatment. J Surg Oncol 1979, 11:21-9.
30. Clark GM, Sledge GWJ, Osborne CK. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987, 5:55-61.
31. Insa A, Lluch A, Prosper F. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999, 56:67-78.
32. Solomayer EF, Diel IJ, Meyberg GC. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000, 59:271-8.
33. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996, 14:2843-77.
34. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998, 351:1451-67.
35. Howell A, Barnes DM, Harland RN. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984, 1:588-91.
36. Anderson WF, Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst 2006, 98:948-51.